Can HSP Recur?
Yes, Henoch-Schönlein purpura (HSP) can and does recur, with recurrence rates ranging from approximately 16-35% in children, typically occurring within the first year after the initial episode.
Recurrence Rates and Timing
HSP recurrence is a well-documented phenomenon. The most robust data from a 16-year nationwide database study found a recurrence rate of 16.4% in children, with an incidence of 7.05 per 100 person-years 1. Other studies report recurrence rates between 26-35% 2, 3.
The average time interval between the first and second episodes is approximately 9 months, though recurrence can occur anywhere from 2-5 months after initial symptom resolution 1, 4. Notably, one case report documented recurrence after 3 years of complete remission, emphasizing that late recurrences are possible 4.
Key Risk Factors for Recurrence
Based on multivariate analysis, the following factors significantly increase recurrence risk:
High-Risk Features:
Renal involvement at initial presentation (adjusted HR 2.41; most consistent predictor across studies) 2, 1
- Specifically, hematuria plus proteinuria is an independent risk factor 2
Prolonged steroid therapy (>10 days; adjusted HR 8.13) 1
Underlying allergic rhinitis (adjusted HR 1.63) 1
Age >6 years at initial presentation 2
Prolonged skin rash duration 3
Elevated inflammatory markers: High platelet count, increased mean platelet volume, elevated platelet-to-lymphocyte ratio (PLR), and elevated CRP 3
Protective Factors:
- Age ≤6 years
- Animal protein restriction during acute phase
- Exercise restriction during initial episode 2
Clinical Implications for Monitoring
Children with renal involvement, those requiring prolonged steroid treatment, and those with underlying allergic conditions require closer surveillance even after apparent resolution. The combination of CBC parameters (PLT, MPV, PLR) and CRP has demonstrated predictive value for recurrence (AUC 0.898, sensitivity 84.6%, specificity 83.7%) 3.
Management Considerations
While KDIGO guidelines address HSP nephritis treatment 5, they recommend:
- Children with persistent proteinuria >1 g/day per 1.73 m² after ACEi/ARB trial should receive 6-month corticosteroid therapy (same as IgA nephropathy)
- Crescentic HSP with deteriorating kidney function should be treated similarly to crescentic IgA nephropathy
Importantly, corticosteroids should NOT be used prophylactically to prevent HSP nephritis (KDIGO recommendation 11.3.1, level 1B evidence) 5.
For recurrent cases with severe manifestations, case reports suggest methotrexate may be effective when corticosteroids fail 6, though this is based on limited evidence.
Common Pitfalls
- Assuming resolution means no further risk: Even after 3 years of remission, recurrence remains possible 4
- Discontinuing monitoring too early: Patients with initial renal involvement require extended follow-up
- Overlooking streptococcal infection: While streptococcal infection is the most common trigger (18.9% of cases), it actually correlates with a 0.4-fold decrease in recurrence risk, suggesting treatment of infection may be protective 7
Bottom line: Adequate clinical intervention targeting modifiable risk factors (diet management, exercise restriction, treatment of infections) during the initial episode may limit recurrence risk, and renal involvement warrants long-term monitoring regardless of apparent clinical resolution.